Dogwood Therapeutics, Inc. (NASDAQ:DWTX)
| Market Cap | 41.81M-80.1% |
| Revenue (ttm) | 0 |
| Net Income | -36.04M-45.7% |
| EPS | -1.06+51.3% |
| Shares Out | 33.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 95,647 |
| Open | 1.24 |
| Previous Close | 1.24 |
| Day's Range | 1.19 - 1.28 |
| 52-Week Range | 1.07 - 7.04 |
| Beta | 1.94 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About DWTX
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
Next catalysts
- Nov 5, 2026Earnings report
Ask Barron about DWTX
$DWTX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in DWTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by DWTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
DWTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
DWTX Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| IPR&D impairment | $9.19M | 50.59% |
| Loss on debt conversion with related party | $6.13M | 33.76% |
| Clinical | $2.30M | 12.67% |
| Chemical, manufacturing and controls | $505.13K | 2.78% |
| Exchange loss, net | $30.57K | 0.17% |
| Regulatory | $4.66K | 0.03% |
| Research and preclinical | $731 | 0.00% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New DWTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to DWTX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in DWTX
| ETF | Est. Holding Size |
|---|---|
| VXFVanguard Extended Market ETF | $178.41K |
| IWCiShares Micro-Cap ETF | $29.98K |
Estimated from each fund’s disclosed top holdings × AUM
DWTX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from DWTX’s recent data — informational, not investment advice